Zentalis Pharmaceuticals (ZNTL) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Zentalis Pharmaceuticals

NasdaqGM•Healthcare•Biotechnology

$3.08-0.02(-0.01%)After hours

Market Cap

$221.82M

P/B

1.5x

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.

How this company scores

WeakMetricSide Score: 37/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Profitability (6/25).

Profitability6/25

Growth8/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality8/25

Strengths

Interest easily coveredProfit converts from growthNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 4.0x5y range 3.1x – 28.2x

Currently near its 7-quarter median.

P/B · 1.5x5y range 0.3x – 10.2x

Currently below its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $221.82M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $0
Q. Revenue: $0
TTM EBITDA: $-152.75M
TTM Op. Income: $-153.37M
Q. Op. Income: $-44.39M
TTM Net Income: $-139.54M
Q. Net Income: $-42.29M
EPS: $-0.59
Shares Out.: $71.33M

$0 in TTM revenue declined 100.0% YoY, reaching $0 last quarter. TTM EBITDA of $-152.75M and TTM operating income of $-153.37M show growth is flowing through to the bottom line. However, net income is negative at $139.54M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is down 100% — a steady trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -4439100000.0%
Net Margin: -4228600000.0%

Op. margin of -4439100000.0% is down 833300000.0% YoY — costs are rising relative to revenue. Net margin at -4228600000.0% Across the last 8 quarters, operating margin has fallen for 3 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: N/A
P/B Ratio: 1.5x

P/S of 0.0x and P/B of 1.5x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $215.33M
Cash: $24.78M
Long-Term Debt: N/A
Book Value: $143.65M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-37.24M
TTM Free Cash Flow: $-128.13M
FCF Margin: N/A
FCF / Net Income: 0.9

TTM FCF of $-128.13M on $-37.24M in operating cash flow. The FCF / Net Income ratio of 0.9x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 2 consecutive quarters — a weakening trend.